Penumbra, Inc. (PEN) Earnings Call Transcript & Summary
November 5, 2025
Earnings Call Speaker Segments
Cecilia Furlong
executiveThanks, Operator. I'm glad all of you could join us today as we review how Penumbra performed in the third quarter of 2025. Our press release is available, and so are the financial tables — which include a reconciliation between GAAP and non-GAAP figures — on our website, www.penumbrainc.com, under the Investors tab. With me on the call are Adam Elsesser, who serves as our Chairman and CEO; Shruthi Narayan, our President; and Maggie Yuen, our Chief Financial Officer. Jason Mills, our EVP Strategy, is also joining us for the Q&A portion. During this call, we will be providing forward-looking statements under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements address matters such as our financial performance, commercialization efforts, clinical trials, regulatory status, quality, compliance, and business trends. We have to flag that a number of risks and uncertainties—among them the ones laid out in our 10-K covering the fiscal year that closed on December 31, 2024, which we submitted to the SEC—mean that what actually happens may end up materially different from anything those statements assert or suggest. Given that, please don't put more weight than is warranted on these forward-looking statements. We'd also urge you to look at our periodic filings with the SEC, including that same 10-K, since they offer a fuller picture of these factors as well as other risks capable of influencing our results down the road or the market price of our stock. Penumbra takes no responsibility for refreshing or altering any forward-looking remarks because of fresh data, upcoming occurrences, changes, or any other reason. During this call, revenue and gross margin figures are given according to GAAP, whereas operating expenses, operating income, and adjusted EBITDA appear on a non-GAAP footing. You can find the matching GAAP figures along with a bridge between GAAP and non-GAAP financial measures in the press release we have made available. When we talk about non-GAAP operating expenses and operating income, we're leaving out the $5 million in costs from Q3 2024 tied to shutting down our immersive healthcare operation. Adjusted EBITDA also doesn't count those wind-down costs, nor does it include stock comp, depreciation, amortization, income tax provisions, or interest income and expenses. With that said, I'll hand things over to Adam.
Adam Elsesser
executiveThank you, Cecilia. Good afternoon, everyone, and thanks for being with us on Penumbra's call for the third quarter of 2025. During Q3, our total revenue came in at $354.7 million, which works out to underlying growth of 17.8% year over year as reported, and 16.9% when measured in constant currency. These strong third quarter results speak to broad-based execution against our strategy, plus meaningful progress in further strengthening how we stack up technologically and in the market across every franchise. U.S. revenue overall reached $275 million in Q3, up 21.5% from the third quarter of 2024. Sales of thrombectomy products in the U.S. rose 18.5% year over year, hitting $192 million. Once again, our VTE franchise drove corporate growth overall, posting 34% growth year over year. U.S. embolization and access revenue came to $83 million, a 29.2% year-over-year increase. That embolization and access growth beat what we had expected, which reflects gains from a dedicated peripheral embolization sales team together with what we've invested in continuous innovation and new product introductions. Outside the U.S., the efforts we made earlier to strengthen our long-term market positioning are starting to bear fruit. We now operate from a position of strength in both portfolio and geography, and in the quarter our commercial execution more than offset the China growth comp headwinds that we keep confronting. Overseas sales came to $79.7 million, which is a 6.6% increase compared with the same quarter last year, and 3% when you strip out currency effects. Dropping down from the top line, gross margin was 67.8%, up 130 basis points from the equivalent period a year ago, while operating income landed at $48.8 million, equal to 13.8% of revenue, and this quarter's operating expense shows the complete effect of scaling up our embolization sales force. We remain on schedule and favorably situated to hit a gross margin level exceeding 70% by the close of 2026, and we anticipate that operating margin growth will exceed gross margin growth for as far out as we can see, given that our focus is on generating profitable growth and an improving profitability profile. Turning now to our U.S. peripheral business. During Q3, our thrombectomy results showed how well CAVT works clinically and how competitively it stacks up, plus our sales team—now focused solely on peripheral thrombectomy—has been executing with more commercial sharpness. For VTE case volume growth, we recorded the biggest quarter-over-quarter gain we've seen in 2025 to date. Meanwhile, our U.S. arterial segment delivered yet another robust showing, as Bolt 7 and Bolt 6X combined helped more physicians move away from open surgery or lytics and toward CAVT. Also in the third quarter, Penumbra received FDA clearance for Lightning Bolt 16 as well as Lightning Flash 3.0. Our 16-French platform now incorporates Lightning Bolt 16, which delivers proprietary modulated aspiration technology. Meanwhile, algorithm accuracy gets a boost from Flash 3.0, thanks to upgrades on both the hardware and software sides. With these launches, our expanding lineup of advanced CAVT devices grows even stronger, and that creates an obvious route to serve the more than 800,000 individuals across the United States dealing with VTE and arterial clot through our CAVT technology. One more thing I'd like everyone to keep in mind: the foundational technology behind our CAVT offerings enjoys protection from a strong patent portfolio. Recently, we secured a favorable decision from the Court of Appeals for the Federal Circuit. That court, in a summary and unanimous decision, upheld the Patent and Trademark Appeal Board's IPR rulings, which validated a number of competitive patents that Penumbra had contested. We will keep defending with vigor every patent and all intellectual property we hold for our CAVT technology. During the TCT and Viva conferences, we shared the landmark findings from STORM-PE. That trial is a prospective, multi-center, randomized, controlled study assessing CAVT alongside anticoagulation against anticoagulation by itself in treating acute intermediate high-risk PE. Shruthi is going to give more specifics about the trial and its outcomes during her prepared remarks. It goes without saying that, considering how the medical community has responded to these data, we hold very high optimism that STORM-PE will serve as a significant catalyst, favorably influencing PE treatment while substantially boosting the count of patients who receive intervention using CAVT. Turning to our U.S. peripheral embolization business: our newly formed sales team of more than 50 members dedicated to embolization achieved robust 21.2% sequential expansion in embolization revenue during the quarter. We think this quarter's performance from that team, together with the sharper focus throughout our full existing coil portfolio, signals a fresh period of sustainable growth for our U.S. embolization franchise. Shruthi will talk about how bringing this new team together is progressing. Moving on to our neurovascular business. Lately, market patterns in the broader U.S. stroke market indicated a modest drop during the third quarter. Even so, our stroke thrombectomy portfolio still produced positive growth along with share gain. In the past, fresh innovation has sparked the stroke market, and we feel optimistic that, with the expected launch of Thunderbolt, we will witness a comparable dynamic unfold. On the neuroembolization side, the recent enthusiasm we have observed for using our Swift Coil in MMA embolization keeps converting into exceptionally robust above-market procedure growth, which adds further to sustainable growth within the U.S. embolization franchise. At this point, I want to bring you up to date on Thunderbolt. In October, we submitted thorough responses addressing all the questions that the FDA had remaining from the 510(k) review. At this stage, we're at the point of resolving any final inquiries or providing whatever clarifications might be needed regarding our answers. For obvious reasons, we'll be careful about what we share concerning Thunderbolt at this time. That said, we remain excited about the prospect of introducing CAVT to the neurovascular space. Taking everything into account, based on our Q3 results and consistent with the patterns we've seen in our business and the target markets we discussed earlier, we're raising our full-year revenue guidance to $1,375,000,000-$1,380,000,000. We're reaffirming the 20%-21% year-over-year growth rate for 2025 in U.S. thrombectomy. Now I will hand the call over to Shruthi, who is going to cover a few specifics regarding the expansion of our sales team and the STORM-PE trial.
Shruthi Narayan
executiveThank you, Adam. Good afternoon, everyone. I'd like to begin with an update on the commercial expansion moves we've made recently. Given how much physician interest in CAVT grew during 2023 and 2024. As we entered 2025, we made the strategic choice to stand up a second peripheral sales team dedicated to our embolization business. That freed our original peripheral sales team to concentrate exclusively on CAVT. During the first half of 2025, we brought on more than 50 additional peripheral embolization sales reps, all reporting up through the peripheral sales leadership group we already had. The buildout and the integration came together very smoothly, and the new team slotted right into our organization. That let the team get RubyXL out there without slowing down what we already had going, and embolization revenue ended up growing 21.2% over the prior quarter in Q3. While we're making this change to how we sell, the people already on board helped bring the new group up to speed and supported passing off embolization case coverage at our accounts; that transition should finish up in Q4, which puts both teams in a good spot heading into 2026, each one able to zero in on its own targets: CAVT and embolization. Turning to STORM-PE — early last week at TCT, Dr. Rob Lookstein walked through the trial's primary endpoints and the main safety findings. At Viva earlier this week, Dr. Rachel Rosowski shared further data on secondary endpoints, among them important physiological and functional measures. In intermediate high-risk PE patients, the trial showed CAVT was better at lowering right heart strain, and its safety profile matched that of the current standard of care. Also, although the study lacked the power to demonstrate statistical significance on secondary endpoints, the results did reveal statistical significance favoring CAVT on several secondary endpoints. Moreover, the first trial results came out in Circulation on Monday. Across the primary endpoint and several secondary endpoints, STORM-PE showed CAVT beat the current standard of care, with CAVT patients recovering sooner and achieving meaningful long-term gains in functional outcomes. The study additionally showcased how the field's leading technology can enable quicker procedures and shorter device times, restoring the standard and benchmarks for what counts as acceptable case duration. Because the trial's procedures called for only limited familiarity with Flash before patients were enrolled in STORM-PE, these robust outcomes further underscore how easy CAVT is to use along with its outstanding safety record. Responses from physicians, both within and beyond the interventional community, have been overwhelmingly favorable. Following those presentations, we're observing a move toward CAVT and away from earlier mechanical thrombectomy choices for PE. Our expectation is that this trend will persist. In addition, we're collaborating with societies and organizations to spread the newly published STORM-PE findings to hospitals, enabling them to revise their existing hospital protocols. This will rank among our biggest focuses during the coming twelve months. Our peripheral and neuro units are performing at a strong level, and we're set up well to keep extending the foundation we've laid so far. As we look toward 2026 and beyond, we remain extremely confident in the long-range strategy we've put together — a strategy grounded in meaningful innovation, in producing data, and in investing in our team — and all of that supports durable, profitable expansion, as well as our ability to reach a great many patients with our technologies. At this point I'll hand things over to Maggie, who will walk through the financial results we posted for the third quarter of 2025.
Maggie Yuen
executiveThanks, Shruthi. Good afternoon, everybody. I'll walk you through our financial performance for Q3 2025. On this call, revenue and gross margin figures are presented on a GAAP basis, whereas operating expenses, operating income, and adjusted EBITDA are non-GAAP. You can find the comparable GAAP figures along with a reconciliation between GAAP and non-GAAP measures in the press release we posted. For the third quarter, which closed on September 30, 2025, total revenues came in at $354.7 million. That represents growth of 17.8% as reported and 16.9% in constant currency versus the third quarter of 2024. Looking at our sales by geography for Q3 2025, 77.5% came from the U.S. and 22.5% from international markets. Our U.S. region posted 21.5% growth, fueled by an 18.5% gain in our thrombectomy franchise and 29.2% growth in embolization and access, which was driven by our RubyXL product, compared with the same period a year ago. As we mentioned before, thanks to China's headwind easing and double-digit growth across the rest of our international regions, our international business is growing again, up 6.6% as reported and 3% in constant currency versus the same period last year. Turning to revenue by product, our global thrombectomy business brought in $236.4 million in Q3 2025, up 15.8% as reported and 15.1% in constant currency compared with the same period last year. This growth was mainly powered by an 18.5% rise in our U.S. thrombectomy business. As we anticipated, our international thrombectomy revenue also grew, up 5.6% versus the same period last year. Our embolization and access business generated $118.3 million in the third quarter of 2025. That's an increase of 22% as reported and 20.8% in constant currency versus the same period last year, mainly driven by higher U.S. peripheral embolization sales stemming from momentum around our successful RubyXL launch, together with the strategic investment we made to expand our U.S. embolization team during the first half of the year. Gross margin for Q3 2025 came in at 67.8%, up from 66.5% in the third quarter of 2024. As we expected, we achieved sequential gross margin improvement of 180 basis points, primarily from favorable regional mix, product mix, and productivity gains. We're very happy with how quickly the team stabilized our RubyXL build — our RubyXL product has an accretive effect on gross margin, and the sales model supports a more efficient working capital dynamic. Beyond that, we're on track to hit our full-year gross margin targets and remain well-positioned to achieve our long-term gross margin profile of 70% by the end of 2026. Now let me move to our non-GAAP operating expenses, non-GAAP operating income and margin, and adjusted EBITDA. Total operating expense for the quarter was $191.6 million, or 54% of revenue, compared with $160 million, or 53.1% of revenue, in the same quarter last year. During Q3 2025, our R&D spending came to $22.7 million, representing 6.4% of revenue. That compares with $22.6 million, or 7.5% of revenue, in Q3 2024. The difference reflects $3.6 million in savings from winding down our immersive business, partially offset by ongoing investment in developing products. For SG&A, Q3 2025 expenses totaled $168.9 million, which was 47.6% of revenue, versus $137.4 million, or 45.6% of revenue, in Q3 2024. As we've noted before, we've brought in targeted hires across our commercial and market access teams. Those additions will help us meet customer demand and take advantage of long-term growth drivers. On a sequential basis, SG&A rose $8.9 million, driven by a full quarter of investment in our embolization sales team plus other variable spending. Now that this buildout is finished, we're set up to achieve sales and operation leverage in the quarters ahead. Operating income came in at $48.8 million, or 13.8% of revenue, versus operating income of $40.3 million, or 13.4% of revenue, during last year's same period. Adjusted EBITDA reached $66.7 million, or 18.8% of total revenue, compared with $56.7 million, or 18.8%, in last year's third quarter. Moving to cash flow and the balance sheet, we closed Q3 2025 with $470.3 million in cash, cash equivalents, and marketable security balance, and no debt — a sequential gain of $45.7 million. That gain reflects better working capital ratios on both the receivable and inventory sides, along with solid profitability. We still anticipate positive operating cash flow trends continuing through 2025 and afterward. Now for 2025 guidance: as Adam said earlier, we're lifting our full-year revenue guidance to $1,375,000,000 -$1,380,000,000. For U.S. thrombectomy, we repeat 20%-21% year-over-year growth for 2025. And lastly, we keep our previously stated 2025 guidance for growth and operating margin expansion. That wraps up our prepared remarks. Operator, please open the call to questions.
Travis Steed
analystHey, congratulations on a strong quarter. Since it's such a hot topic right now, I'll kick things off with Thunderbolt. From what you're saying, it seems like you're much nearer to getting the green light than before. My guess is there haven't been any surprises in the exchanges with the FDA, but I'm curious how you're viewing this product once it launches — what portion of the market you might capture, and how much. Also, when will investors get a look at the Thunderbolt data? If you could say whether approval might come before the year is out, or not, any other insight into the FDA review would be useful.
Adam Elsesser
executiveGreat. Thank you, Travis. There's a lot of complexity packed into that question, so I'll do my best to address everything I can. Perhaps we should begin with the review process and offer a bit more detail, and after that we can discuss what things look like at a certain point down the road. I'm aware there's been plenty of commentary and speculation regarding when this process will wrap up. I'd like to perhaps reset expectations on both the process and its timing, because I believe there may be some misperceptions out there. Thunderbolt is an entirely new product. It hasn't received approval yet. It isn't merely pursuing an additional indication. I'm aware that previously, people have drawn comparisons to items already being sold that come with a track record, that carry safety data that the FDA naturally reviews and gathers, and in those cases all that's being sought is an added indication. That's a separate scenario. The timeframe tends to be shorter in those instances. When it comes to completely new products, those reviews, based on what we've seen in the neuro division at least, can occasionally be lengthy. To illustrate, the timing here isn't essentially different from what we saw with our initial RED72 Silver Label, which involved an update to a product already on the market, though it was a new product featuring new materials and so forth. It takes time because the FDA — and I give them credit for this — is extraordinarily meticulous. There's nothing unusual regarding this process or its timing, yet we're feeling at minimum hopeful and optimistic. Obviously, without revealing competitive details about what a launch would involve — and clearly, we don't wish to do that. Naturally, we're prepared to bring this product to market, and we're thrilled about it for when that moment arrives and we're able to proceed; we'll remain optimistic. Once more. We need to exercise some caution until we receive a clearance letter, which would give you further specifics on all this. Okay?
Travis Steed
analystThat makes sense. Now that STORM-PE secondaries came out earlier this week and you've spoken with physicians, maybe a follow-up there. I'm curious how you view the effect on the market, how it might speed things up, and the chance to gain share because of the safety profile on the device.
Adam Elsesser
executiveYeah, a few interesting and exciting developments have occurred. First, the response to the data among the medical community has simply been unbelievably favorable. I think people who attended TCT, VIV, or both witnessed that. They sensed it. The safety, the endpoints, the primary endpoint, and naturally, the secondary endpoints are truly, truly favorable and robust and will make a major difference for non-interventionalists too. Beyond that, the product's safety profile was genuinely remarkable. I believe that has caused a number of interventionalists who historically have not used our product to call and want to begin performing cases, and they have performed cases in the last really week since last Sunday with our product truly for the first time, and multiple cases. That momentum is exciting as the field shifts away from the older technology that kind of launched the field toward the more modern CAVT technology. Regarding the non-interventional community and what that response looks like, which is truly central to building this market and expanding it, Shruthi perhaps can offer you some further remarks. She has had a number of conversations with people and can share her perspective.
Shruthi Narayan
executiveYes, thank you, Adam. So, regarding the non-interventional community, for instance, there have been particular discussions involving pulmonologists and hematologists, and all of them are now quite pleased that validation exists showing right heart recovery subsequently results in the kind of six-minute walk test improvement that appeared in the functional outcomes; they are currently undertaking efforts to begin revising protocols at their own institutions and to begin ensuring a growing number of patients obtain access to care. That remark was delivered by Dr. Rachel Rosowski from the podium immediately at the conclusion of the presentation. At this point, various physicians within the non-interventional community are reviewing their respective hospital protocols in order to implement those revisions. Ever since Rachel's presentation came out on Monday, I have personally held discussions with physicians who reacted in the same way. I believe this is genuinely encouraging for the field, and ideally it will expand access to care for many more patients.
Travis Steed
analystThat's great. Thanks a lot.
Adam Elsesser
executiveThank you.
Robbie Marcus
analystOh, excellent. Congrats on a solid quarter. I appreciate you fielding the questions. I'd like to discuss margins here. I suppose I'll avoid the revenue topics. You restated the gross margin and operating margin guidance, so I'm just curious how you view the capacity to push margins upward. Will Thunderbolt play a major role in moving those higher compared with what you initially had in mind? How ought we to consider the effect of tariffs and the way that shaped margins for full-year 2025? Thank you.
Adam Elsesser
executiveI'll begin quickly, and then Maggie is able to handle the bulk of those. Every one of our CAVT products carries extremely, extremely robust margins. Thus each of them, whether that's simply Thunderbolt or any other of the categories we've devoted considerable time to discussing, possesses that capability as the mix shifts. Another point is that with the latest coil we introduced, it is likewise accretive. I believe we feel fairly confident, though Maggie might walk through a few of the finer details.
Maggie Yuen
executiveYes, yes, thank you. Regarding the other elements, what you're seeing this quarter is favorable, particularly when looking at regional mix, as we've experienced considerable growth in the U.S., along with ongoing product mix benefits and the operations teams' recovery in stabilizing RubyXL yield gains and productivity. As we move into Q4, that pattern should persist. My expectation is that we'll keep seeing quarter-over-quarter gains from product mix, regional mix, and productivity improvements, plus some leverage from volume. I believe what showed up this quarter already captured a portion of tariff effects. Tariffs aren't having a significant effect on us, though there's still a slight one, yet the figures and direction we've observed already account for us absorbing those headwinds.
Robbie Marcus
analystGreat. Maybe just a quick follow-up. If I zoom in specifically on thrombectomy — both in the U.S. and outside it, although I'd guess especially here in the U.S. It's been decelerating all year long. My assumption is that a lot of this mirrors softness in the stroke segment, offset by very strong venous performance, category expansion, and Penumbra's own gains. What's your view on this — should we reasonably assume the declining pattern continues, or do you think stroke could level off as we move toward 2026, with venous making up for it and driving things back toward faster growth? Thanks so much.
Adam Elsesser
executiveYes, yes, Robbie — I appreciate it. I also want to thank you for using your question to draw attention to what's happening in the market. Your description is spot on. Clearly, VTE has been the growth driver, quarter after quarter, and part of that comes from the market expanding, while a meaningful portion reflects share gain. Arterial, I'd say, has also performed very, very well. When it comes to stroke, the past couple of quarters have clearly been the weak spot. Even so, we've maintained our position and taken advantage of that situation to keep gaining share, so we're not negative in that area. Our business isn't shrinking — it simply isn't expanding at the same rate, obviously. During all the time we've participated in the stroke sector, this pattern has shown up repeatedly. It's nothing unfamiliar, and if you've followed our company across the years, you already understand that. These things arrive in cycles rather than following a steady line. So right now, there's no real reason for alarm. That said, when you bring in genuinely breakthrough technology — something that isn't just a variation on what already exists — that tends to act as a fairly powerful trigger. So that would likely provide a boost. Yet regardless of that, the market generally moves up and down somewhat, and our expectation is that it will recover. Typically, Q4 tends to be a period when we see expansion, historically speaking, in terms of the quantities that rise. That said, looking ahead, I feel positive overall — it simply arrives in these cycles.
Robbie Marcus
analystGreat. Thanks a lot, Adam.
Adam Elsesser
executiveThank you.
Larry Biegelsen
analystAfternoon. Appreciate you taking my question. Nice quarter, Adam — congratulations. Adam, I'd like to ask about MBO access, which here in the U.S. was exceptionally strong during Q3. In fact, MBO access globally expanded at a quicker pace than thrombectomy globally. Was there any element in Q3 you'd describe as one time? How much of that strength came from RubyXL as opposed to Swift, the one you called out? Looking ahead, ought we to anticipate that MBO access will now grow faster than thrombectomy? I had one follow-up.
Adam Elsesser
executiveYeah, that's a great question. Addressing the immediate question first: nothing in this quarter was one time. The two items that genuinely stood out in the U.S. — those were what was driving it. Two items concerning the peripheral side of the business. First, we now have a dedicated team, something we haven't had for a while. That's where their attention goes. Obviously, across the last few years, our peripheral team's attention had been divided between our coils and our thrombectomy, which made doing both well pretty hard. I believe that's a good sign for what's ahead, that the integration, as Shruthi mentioned, was truly seamless. Honestly, I was incredibly impressed with every member of that team and with the sales team's leadership for enabling that to happen that way. It's not. A normal process to be that seamless, and it truly was. I think we're in really good shape. What this demonstrates, I think, is that a huge market and appetite exist for our very distinctive products that differ from others on the market. That will continue, I believe. I said as much in my prepared remarks. Turning to the neuro side, watching that is really fascinating to me. Growth there keeps happening. The number of cases people are doing in general for MMA embolization has risen notably, and more and more people are switching to our product because of its safety profile compared to more traditional means of treatment. We're pretty optimistic about this business, I think. Together with the thrombectomy, I think they both become equal drivers of growth. Obviously, you're going to see the. A quarter is the quarter that you launch a product, have slightly bigger growth on a sequential basis. Overall, looking ahead, we're not going to be viewing that business as dragging down our growth. I think both MBO and thrombectomy will be an important part of our growth in 2026 and beyond.
Larry Biegelsen
analystThat's useful. Hey, Adam, a fast one regarding the guidance. It really seems as though the guidance points to a slowdown in Q4. I want to know the reason. For 2025, the outlook of 15 to 16% includes roughly a 4% drag from China. So at 15%-16% on a reported basis, is there any cause for growth to decelerate next year? I appreciate you taking the question.
Adam Elsesser
executiveYeah, listen. I believe we've made it quite plain that we've learned our lessons when it comes to guidance, and we don't get ahead of ourselves. Clearly we won't provide what you might call backdoor guidance for 2026. That's not something I'll do; our guidance will come on the fourth quarter call. Of course, if you pay close attention, and you did, to what we've just told you about our business and our position; we feel especially good about our position, not only this quarter, but for some time ahead, well into next year and the years after.
Larry Biegelsen
analystAll right. Thank you, Adam.
Adam Elsesser
executiveThank you.
Joanne Wuensch
analystThanks a lot for taking my question. I'd like to explore overseas revenue a bit, if I may; from what you've said, it sounds like the challenges in China are fading. How far along is that process? Had we stripped out those challenges, what figure would OUS growth have reached in this quarter? Thank you.
Shruthi Narayan
executiveOh, yeah, thank you. I suppose. Essentially, come next year, in the early part of next year, quite a bit of the pressure we're facing will be quite small. We do have a bit of China revenue this year, but. For next year, I'd view that as a headwind. As for how the rest of the international region is growing, we mentioned that. Apart from China, the remaining international regions are seeing double-digit growth. I believe in earlier quarters, at times we pointed out that the thrombectomy portion of the OUS often expands in the mid-teens. So that's sort of been our pattern all through this year, and there's still plenty of growth momentum going into next year.
Joanne Wuensch
analystThank you.
Adam Elsesser
executiveThank you.
Vijay Kumar
analystHey everyone. I appreciate you answering my question, and congratulations on a strong spring season. Adam, I'll start with you, and it's about STORM-PE. In the past, I believe you suggested STORM-PE could potentially transform how care is delivered in the clinic. Now that the primary and secondary endpoints have come out, I'm wondering whether that's sufficient to shift practice. Will we begin to observe a faster uptake in procedures, or do certain obstacles remain when it comes to adopting thrombectomy and managing PE cases?
Adam Elsesser
executiveOkay, so honestly, all I can share is what has reached us over roughly the past seven days. A great many discussions. What I can say is that quite a few non-interventionalists — and I believe Shruthi mentioned two pulmonologists she personally spoke with — along with several other non-interventionalists, have told us they intend to take the lead at their own hospitals in revising the protocols in light of these findings. As I see it, the response — the favorable response — to these findings has been consistent among both interventionalists and non-interventionalists. So now the real work begins: getting hospital protocols updated. As we've noted, and as you heard from members of our steering committee, guidelines tend to trail behind practice at times. My expectation is that you'll witness shifts in hospital behavior and protocols, and then guidelines will catch up to that. It has truly been. Encouraging to witness this level of enthusiasm, and not only among interventionalists but also among non-interventionalists, who recognize they now possess a highly compelling option for situations where they know their patients require something more substantial. I'd call it a positive day for the field and a significant moment; our optimism about it runs deep.
Vijay Kumar
analystGot it. Then perhaps a question about the P&L. Our gross margin improved by 180 basis points quarter over quarter. On SG&A, the increase was pretty remarkable — 25%. Did any timing advantage or timing effect, so to speak, play a role in SG&A OpEx? Or is this figure the result of being proactive as you examine the pipeline, with certain PP products reaching fruition?
Shruthi Narayan
executiveYeah, no, I appreciate you asking that. Regarding operating expenses, essentially every bit of the uptick you're seeing comes from what we've put into our embolization team and the structure of our commercial team. That investment, or the build-out, is basically finished as of this quarter or the one before it. From here on out, we'll begin to see greater leverage, and the amount we're investing is going to be less than what showed up earlier in the year.
Vijay Kumar
analystUnderstood. Thank you.
Adam Elsesser
executiveThank you.
Brandon Vazquez
analystHey, everybody. Thanks for fielding the question. I'd like to keep following that STORM-PE thread for a moment, though I'll pose this one a bit differently. It seems there may be an early gain from interventionalists who already do more mechanical thrombectomy. Another tertiary upside that could emerge is that smaller hospitals doing zero thrombectomy right now may begin offering these procedures. The data showed us a quite shallow learning curve, with many naive users participating in this trial. So here's how I'll frame the question: first, walk us through the timelines and what you expect when it comes to activating some of these accounts, and how hard or simple that may prove. And once you've got a foothold in PE treatment, are there additional venous opportunities, now that the Lightning has been placed in these smaller hospitals, that you could also pursue?
Adam Elsesser
executiveYeah, quite a lot. Regarding your question. In a respectful amount of time, I'll attempt to give you an answer that's fairly complete yet brief. The layers of opportunity here are numerous. There are practices not treating everyone, which describes most of them, who will now hopefully begin altering their internal protocols. There are hospitals that essentially don't perform intervention for PE, which, as you mentioned, might now embrace it. Occasionally that carries an added benefit, since when you're treating PE, you're genuinely tied to its cousin, DVT treatments. A number of those sites are employing our technology for arterial work, for instance, which is a somewhat different dynamic. There's a degree of overlap. Taken together, what this does is genuinely shine a light on the newest technology, which is CAVT. The speed of those cases, the safety profile of those cases. Previously, as you're aware, we've discussed and presented quite strong data regarding the health economics of that, which supports doing this. It's a procedure that is plainly validated not just clinically, but economically too. I believe it truly creates an opening for many people. I personally had an experience at TCT speaking with a cardiologist who leads a very well-known national practice, yet their group generally doesn't handle PE; another specialty at their hospital covers it. Upon hearing the data, they were especially eager to get involved, assist their colleagues, and expand the coverage capacity quite substantially. That was merely one of numerous, numerous conversations. It requires some time. None of it can occur in a single quarter, but it positions us really well for 2026.
Brandon Vazquez
analystAll right. Let me ask something else as a follow-up. I apologize if all of you already covered this territory earlier, but this is my first time getting a bit more information about Lightning Flash 3.0. Could you take a moment to walk through the schedule for a wider rollout, how significant it is, and where you expect 3.0 to deliver advantages compared with 2.0? Thank you, everyone.
Shruthi Narayan
executiveYes. Regarding 3.0, like Adam mentioned during the prepared remarks, it truly combines a hardware refresh with a software one. Its effect is a genuine boost to fidelity. That translates to these cases reaching 25-minute device times, as STORM-PE showed, and that's genuinely the quickest available anywhere at present. With Flash 3.0, things will get quicker still and improve further regarding the overall safety profile, blood mitigation, and everything our physicians have by now essentially grown to anticipate. By cutting those case times down even more, this pushes all of that substantially ahead.
Bill Plovanic
analystYes, excellent. Thank you. Good evening, and I appreciate you fielding my questions. To start, I recognize that with the guidance, being cautious is your aim, yet the top end of what you've provided reflects a 2% increase quarter over quarter. During the previous year and the one before that, you achieved gains of 4.8% and 5.1%. So I'm simply attempting to figure out whether there's some particular issue worrying you, such that your guidance is only 2% growth rather than the 5% that would match what happened across those prior two years?
Adam Elsesser
executiveIt isn't a matter I examine through each of the different lenses available. What I focus on is the amount we surpassed expectations by and the amount we elevated guidance by. My view is that this is a fairly robust guide upward. Clearly, we have no desire to move too fast ahead of where we are. There's a great deal of constructive effort ahead of us in the coming stretch. Give us room to begin. Let's start moving. STORM-PE has only been underway for a week. My sense is we'll be fairly at ease. We have a few products slated for release in peripheral and neuro strong. Be patient with us; things will turn out well.
Bill Plovanic
analystAlright. To add a follow-up, once more regarding the FDA, I genuinely value the update, quite a bit of detail provided today. What I want to know is whether the FDA is asking for further testing and/or clinical data from your side, or has this become simply a series of exchanges at this stage?
Adam Elsesser
executiveYes. Once more, I prefer to stay cautious. I made that quite evident. As I stated during my prepared remarks, every question we had gotten as of that moment has already been answered quite comprehensively; that work is complete; they have now entered a period in which they can, clearly, seek clarifications or pose further questions. I'm unable to say what those will look like at this point; we have obviously gone through, over some stretch of time now, extremely, extremely detailed inquiries, just like any new product reviewed within the neuro division. Entirely reasonable and not entirely surprising.
Bill Plovanic
analystDoes the shutdown have any effect on how they're responding, or do they keep working through it?
Adam Elsesser
executiveOn a day-to-day level, I'm not able to address that, but up to this point, no delay of any kind has come up for us as a result of the shutdown. Clearly, that process unfolds in real time and without interruption. That's something I can't address — what could occur at the close of this week, or the following week, or anything along those lines.
Bill Plovanic
analystAll right, that's excellent. I appreciate you fielding my questions.
Adam Elsesser
executiveCertainly.
Michael Sarcone
analystGood afternoon, and I appreciate you fielding the questions. There has been considerable attention on STORM-PE and pulmonary embolism. Your U.S. VTE business keeps expanding at a robust pace. Perhaps you could share the most recent developments regarding trends in the DVT portion of the business and your perspective on growth in that area.
Shruthi Narayan
executiveThank you. That is an excellent question; regarding DVT, what we are once again observing is simply a favorable reaction to Flash 2.0. We have noted that the VTE segment overall has been growing steadily over the past several quarters, and we anticipate that pattern will persist. As physicians learn about the Storm results, you will simply see them begin embracing the technology for PE. If they have not yet utilized our offerings for DVT, that dynamic will become apparent. I believe this positions us quite favorably going forward. I hope that addresses your question.
Michael Sarcone
analystThat answers it — genuinely useful. One brief extra question on that point: previously, you mentioned that DVT is somewhat distinct because the emphasis tends to be on the health economics angle, plus collaborating with certain hospital accounts, if I'm understanding correctly. Is that still an area of emphasis for you, and will you keep delivering that type of health economic evidence regarding DVT?
Shruthi Narayan
executiveWithout a doubt. We are beginning to observe those findings being shared at various conferences — specifically a few of the market access data sets, developed alongside the Vizient and Premier databases. Word about this is starting to reach the physician community. In addition, our hospital engagement team is out there holding active discussions with various individuals inside hospitals to get that information across. Another thing you'll notice is that the STORM-PE benefit, once again, extends to the broader VTE segment as a whole. You'll simply witness greater enthusiasm among hospitals about treating these patients. The level one evidence that is available now is going to be beneficial on the DVT side too.
Michael Sarcone
analystGreat, thanks.
Pito Chickering
analystHey everyone, good afternoon, and thanks for taking my questions. I have a few follow-ups regarding U.S. thrombectomy. Could you discuss how market share compared to market growth during the quarter? Also, can you put a number on the new accounts you brought on this quarter, and how do you expect that to look in Q4 after the Storm trial?
Adam Elsesser
executiveYeah, of course. You can find comparative data from other companies out there. Clearly, a large portion of this occurred before Storm was released, but a significant amount of that related to market share. In my view, that fact is already understood. Looking only at how many new accounts were added doesn't give you the full picture, since each account clearly contains multiple physicians. One might prescribe a particular product while another goes with a different one, and that blend exists across the board — so it isn't a solid metric. As for those who had been on some other option and then moved over to us, that trend has carried on throughout the entire year, obviously starting at the close of last year and continuing right through this one. The part that caught us off guard was. It's probably not a shock, though it's good to see — in just the past week, since the data and the safety profile were among the reasons people pointed to for switching, we've had patients move off the older technology onto the newer one. Everything points to that trend carrying on. Looking ahead, I believe it'll be a mix of ongoing share migration away from the older kind of technology toward the newer CAVT. What I expect to unfold across roughly the next twelve months is a rising count of patients who get treated. Those two things are linked, in my view. DVT and PE feed into one another in that respect. My sense is you'll see growth during the coming two to three years.
Pito Chickering
analystAll right. When I step back and consider how the market is expanding, what's your estimate for the number of PERT teams that came into existence during this year? And what does the picture look like from the hospital side following the Storm trials? Last week at TCT, there certainly appeared to be considerable enthusiasm regarding launching additional PERT programs. Thank you.
Adam Elsesser
executiveYes. Well, I'd say there are two distinct categories of PERT teams. You have the formal ones, which are likewise members of the PERT consortium. Then you have a great many local PERT teams that have not become part of the PERT consortium. In certain cases, smaller hospitals are simply newer to this process. What made me quite happy was that at the start of TCT, the PERT consortium revealed a rather major initiative extending across the coming couple of years aimed at sharply boosting how many members their consortium has, plus genuinely assisting in getting them equipped with the most up-to-date technology and the notion that these individuals can receive help in a novel manner. I believe there's abundant energy waiting to be unleashed. Following the TCT meeting, and at Viva too, it became quite evident that. People will either establish informal PERT programs — meaning a cross-functional set of individuals who care for these patients in a different fashion — or they will formalize them and join the PERT consortium. In either scenario, I think we are witnessing an enormous shift in energy and attention when it comes to pulmonary embolism patients.
Pito Chickering
analystGreat. Thanks so much.
Adam Elsesser
executiveThank you.
Ryan Zimmerman
analystThanks for fitting me in. That means a lot. I'll get both of my questions out there right away. Regarding the interim update on STRIKE-PE coming out of TCT, we haven't discussed it much. I'd like to hear your big-picture take on it. We reviewed the data, nice RVLV changes. I believe there are definitely other elements that stood out or have been on people's minds. I'm interested in your high-level view. The second question is for Shruthi, about embolization and access. You brought it up. Normally these markets don't expand at the rates you're witnessing. Is it purely the products? Is it increased utilization of MMA? I'd just like to know if you could speak in detail about what will sustain this going forward. Thanks.
Shruthi Narayan
executiveYeah. Yeah. Excellent questions. Regarding the first one about STRIKE-PE, as you mentioned, clearly STORM-PE is the main focus at the moment, but STRIKE-PE definitely validates the longer-term advantage of CAVT. As you might remember, that trial extends to one year and examines functional outcomes. Over the longer term, how do these patients fare out to one year? It simply strengthens the total evidence base. At Viva, a particular subset was shown focused only on the Flash product's use among these patients and their follow-up through one year. At TCT, a data set existed concerning the high-risk PE patients, demonstrating that CAVT can deliver genuine benefit for that group. All in all, I believe it's simply an expanding body of evidence in PE. I think what you'll begin to observe is that PERT teams and PE teams everywhere will increasingly concentrate on treating a greater number of patients with CAVT. For your second question, regarding the embolization products and that whole category, the team is now set up to dedicate 100% of its attention to our embolization products. Although we lead the market, we don't have 100% of it yet. I believe there's still room to keep growing it. Our physicians adore how the coils work. This focus enables our team to go out and ensure the coils reach everyone. Beyond that, MMAs are a relatively newer procedure in general. As Adam mentioned, some of the more traditional choices like embolics have long been around. The coils, how they function, our coils in particular truly have been. Our physicians have truly been reacting positively to that. I think what you're seeing here is a mix of what we offer through the peripheral embolization focus, plus the rising number of procedures within the MMA category.
Ryan Zimmerman
analystThanks, Shruthi.
Cecilia Furlong
executiveThanks, Operator. Our management team and I want to express our appreciation once more to everyone for being with us today, and for the attention you show toward Penumbra. We're eager to bring you our update during the call on the fourth quarter.
Operator
operatorThat wraps up our session for today, everyone, and we appreciate your joining us. You're free to hang up at this point.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Penumbra, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Penumbra, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Penumbra, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.